Abstract
Multiresistant Gram-negative bacteria are the prime mover of nosocomial infections. Some are naturally resistant to antibiotics, their genetic makes them insensitive to certain families of antibiotics and they transmit these resistors to their offspring. Moreover, when bacteria are subjected to antibiotics, they eventually develop resistance against drugs to which they were previously sensitive. In recent years, many bacteriocins active against gram-negative bacteria have been identified proving their efficacy in treating infections. While further investigation remains necessary before the possibilities for bacteriocins in clinical practice can be described more fully, this review provides an overview of bacteriocins acting on the most common infectious gram negative bacteria (Klebsiella, Acinetobacter, Pseudomonas aeruginosa and E. coli).
Keywords: Bacteriocins, Enterobacteriacae, gram negative bacteria, nosocomial infections.
Infectious Disorders - Drug Targets
Title:Bacteriocins Active Against Multi-Resistant Gram Negative Bacteria Implicated in Nosocomial Infections
Volume: 15 Issue: 1
Author(s): Hanen Ghodhbane, Sabrine Elaidi, Jean-Marc Sabatier, Sami Achour, Jeannette Benhmida and Imed Regaya
Affiliation:
Keywords: Bacteriocins, Enterobacteriacae, gram negative bacteria, nosocomial infections.
Abstract: Multiresistant Gram-negative bacteria are the prime mover of nosocomial infections. Some are naturally resistant to antibiotics, their genetic makes them insensitive to certain families of antibiotics and they transmit these resistors to their offspring. Moreover, when bacteria are subjected to antibiotics, they eventually develop resistance against drugs to which they were previously sensitive. In recent years, many bacteriocins active against gram-negative bacteria have been identified proving their efficacy in treating infections. While further investigation remains necessary before the possibilities for bacteriocins in clinical practice can be described more fully, this review provides an overview of bacteriocins acting on the most common infectious gram negative bacteria (Klebsiella, Acinetobacter, Pseudomonas aeruginosa and E. coli).
Export Options
About this article
Cite this article as:
Ghodhbane Hanen, Elaidi Sabrine, Sabatier Jean-Marc, Achour Sami, Benhmida Jeannette and Regaya Imed, Bacteriocins Active Against Multi-Resistant Gram Negative Bacteria Implicated in Nosocomial Infections, Infectious Disorders - Drug Targets 2015; 15 (1) . https://dx.doi.org/10.2174/1871526514666140522113337
DOI https://dx.doi.org/10.2174/1871526514666140522113337 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets Ponatinib: A Review of Efficacy and Safety
Current Cancer Drug Targets Control of Protein Synthesis in Malignant Transformation - the Role of eIF4E and the eIF4E Binding Proteins in the Regulation of Apoptosis
Current Cancer Therapy Reviews Epigenetic Regulation of Gene Expression as an Anticancer Drug Target
Current Cancer Drug Targets Recent Progress on Antifungal Drug Development
Current Pharmaceutical Biotechnology Melatonin Induces Apoptosis and Inhibits the Proliferation of Cancer Cells via Reactive Oxygen Species-mediated MAPK and mTOR Pathways
Clinical Cancer Drugs Synthesis and Evaluation of New Thiazolyl Hydrazone Derivatives as Potential Anticancer Agents
Letters in Drug Design & Discovery Look Into My Onco-forest - Review of Plant Natural Products with Anticancer Activity
Current Topics in Medicinal Chemistry RNA Interference: A New Targeted Tumour Therapy?
Current Cancer Therapy Reviews Genistein Affects Expression of Cytochrome P450 (CYP450) Genes in Hepatocellular Carcinoma (HEPG2/C3A) Cell Line
Drug Metabolism Letters Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Busulphan in Blood and Marrow Transplantation: Dose, Route, Frequency and Role of Therapeutic Drug Monitoring
Current Clinical Pharmacology Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets The Shape of the Messenger: Using Protein Structure Information to Design Novel Cytokine-based Therapeutics
Current Pharmaceutical Design Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design New Antitumour Natural Products from Marine Red Algae: Covering the Period from 2003 to 2012
Mini-Reviews in Medicinal Chemistry CAR T-cell Therapy: A New Era in Cancer Immunotherapy
Current Pharmaceutical Biotechnology Whole Cell Biocatalysts for the Preparation of Nucleosides and their Derivatives
Current Pharmaceutical Design